🎉 M&A multiples are live!
Check it out!

Vanda Pharmaceuticals Valuation Multiples

Discover revenue and EBITDA valuation multiples for Vanda Pharmaceuticals and similar public comparables like Vivoryon Therapeutics, Julphar, and Pharming.

Vanda Pharmaceuticals Overview

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.


Founded

2002

HQ

United States of America
Employees

368

Website

vandapharma.com

Financials

LTM Revenue $206M

LTM EBITDA n/a

EV

-$108M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Vanda Pharmaceuticals Financials

Vanda Pharmaceuticals has a last 12-month revenue of $206M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Vanda Pharmaceuticals achieved revenue of $199M and an EBITDA of -$32.5M.

Vanda Pharmaceuticals expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Vanda Pharmaceuticals valuation multiples based on analyst estimates

Vanda Pharmaceuticals P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $193M $199M XXX XXX XXX
Gross Profit $230M $178M XXX XXX XXX
Gross Margin 119% 89% XXX XXX XXX
EBITDA -$10.9M -$32.5M XXX XXX XXX
EBITDA Margin -6% -16% XXX XXX XXX
Net Profit $6.3M $2.5M XXX XXX XXX
Net Margin 3% 1% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Vanda Pharmaceuticals Stock Performance

As of April 15, 2025, Vanda Pharmaceuticals's stock price is $4.

Vanda Pharmaceuticals has current market cap of $254M, and EV of -$108M.

See Vanda Pharmaceuticals trading valuation data

Vanda Pharmaceuticals Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$108M $254M XXX XXX XXX XXX $-0.55

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Vanda Pharmaceuticals Valuation Multiples

As of April 15, 2025, Vanda Pharmaceuticals has market cap of $254M and EV of -$108M.

Vanda Pharmaceuticals's trades at -0.5x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Vanda Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Vanda Pharmaceuticals and 10K+ public comps

Vanda Pharmaceuticals Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$108M XXX XXX XXX
EV/Revenue -0.5x XXX XXX XXX
EV/EBITDA 3.3x XXX XXX XXX
P/E -13.5x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 6.6x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Vanda Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Vanda Pharmaceuticals Valuation Multiples

Vanda Pharmaceuticals's NTM/LTM revenue growth is 22%

Vanda Pharmaceuticals's revenue per employee for the last fiscal year averaged $0.5M, while opex per employee averaged $0.6M for the same period.

Over next 12 months, Vanda Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Vanda Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Vanda Pharmaceuticals and other 10K+ public comps

Vanda Pharmaceuticals Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 3% XXX XXX XXX XXX
EBITDA Margin -16% XXX XXX XXX XXX
EBITDA Growth 197% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 6% XXX XXX XXX XXX
Revenue per Employee $0.5M XXX XXX XXX XXX
Opex per Employee $0.6M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 37% XXX XXX XXX XXX
Opex to Revenue 115% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Vanda Pharmaceuticals Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Vanda Pharmaceuticals M&A and Investment Activity

Vanda Pharmaceuticals acquired  XXX companies to date.

Last acquisition by Vanda Pharmaceuticals was  XXXXXXXX, XXXXX XXXXX XXXXXX . Vanda Pharmaceuticals acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Vanda Pharmaceuticals

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Vanda Pharmaceuticals

When was Vanda Pharmaceuticals founded? Vanda Pharmaceuticals was founded in 2002.
Where is Vanda Pharmaceuticals headquartered? Vanda Pharmaceuticals is headquartered in United States of America.
How many employees does Vanda Pharmaceuticals have? As of today, Vanda Pharmaceuticals has 368 employees.
Who is the CEO of Vanda Pharmaceuticals? Vanda Pharmaceuticals's CEO is Dr. Mihael Hristos Polymeropoulos,M.D..
Is Vanda Pharmaceuticals publicy listed? Yes, Vanda Pharmaceuticals is a public company listed on NAS.
What is the stock symbol of Vanda Pharmaceuticals? Vanda Pharmaceuticals trades under VNDA ticker.
When did Vanda Pharmaceuticals go public? Vanda Pharmaceuticals went public in 2006.
Who are competitors of Vanda Pharmaceuticals? Similar companies to Vanda Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Vanda Pharmaceuticals? Vanda Pharmaceuticals's current market cap is $254M
What is the current revenue of Vanda Pharmaceuticals? Vanda Pharmaceuticals's last 12-month revenue is $206M.
What is the current EV/Revenue multiple of Vanda Pharmaceuticals? Current revenue multiple of Vanda Pharmaceuticals is -0.5x.
What is the current revenue growth of Vanda Pharmaceuticals? Vanda Pharmaceuticals revenue growth between 2023 and 2024 was 3%.
Is Vanda Pharmaceuticals profitable? Yes, Vanda Pharmaceuticals is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.